Company profile
Cocrystal Pharma, Inc.
NASDAQ: COCP · Healthcare · Biotechnology
#795 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
31DFH 36DQ 19GM —SS 47
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, listing tenure · ↓ revenue growth (YoY), disclosure history
Methodology →Revenue TTM
$330.0k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$8.8M
Employees
10
as of 2026-08-22
Market cap
$15.9M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.0M$2.0M2020
Net income-$8.8M-$8.8M2025
Operating income-$9.0M-$9.0M2025
Total assets$9.7M$9.7M2025
Liabilities$3.4M$3.4M2025
Equity$6.3M$6.3M2025
Revenue trend
FY2012 – FY2020 · USD
FY12
FY19
FY20
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Cocrystal Pharma, Inc.’s revenue?
Cocrystal Pharma, Inc. booked $2.0M in FY2020 revenue, contracting 69% year over year — slower than 86% of Healthcare companies we track, at a -438.5% net margin.
Peers · Healthcare
Humacyte, Inc.27DNutriband Inc.52DDianthus Therapeutics, Inc.49DSagimet Biosciences Inc.36DOramed Pharmaceuticals Inc.61CRapid Dose Therapeutics Corp.38DNeighbors
King →Key facts
CEOJames E. Sapirstein
SectorHealthcare
IndustryBiotechnology
HeadquartersBothell, WA
ExchangeNASDAQ: COCP
Employees10
IPO date2012-02-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.